Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Acute Lymphocytic Leukemia in Children

Acute Lymphocytic Leukemia in Children Among 108 children under 20 years of age with acute lymphocytic leukemia, vincristine sulfate and prednisone induced complete remissions in 96% (43) of the patients with newly diagnosed disease and in 83% (52) of the previously treated patients. Methotrexate administered orally or intramuscularly twice a week maintained the remissions similarly. The median duration of remission for 42 newly treated patients was 10.4 months (orally) versus 8.9 months (intramuscularly), and for 51 previously treated patients it was 5.1 months (orally) and 4.9 months (intramuscularly). The duration of methotrexate-maintained remission was shorter for subsequent remissions especially if a previous remission had been maintained with methotrexate. Possibility of a new type of toxic reaction occurring during methotrexate maintenance is suggested by the high frequency of pneumonitis (38 of 93 children). Other toxic manifestations were controlled by diminished dosages of methotrexate. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Acute Lymphocytic Leukemia in Children

,
JAMA , Volume 207 (5) – Feb 3, 1969

Loading next page...
 
/lp/american-medical-association/acute-lymphocytic-leukemia-in-children-seYUfguRGv
Publisher
American Medical Association
Copyright
Copyright © 1969 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1969.03150180053011
Publisher site
See Article on Publisher Site

Abstract

Among 108 children under 20 years of age with acute lymphocytic leukemia, vincristine sulfate and prednisone induced complete remissions in 96% (43) of the patients with newly diagnosed disease and in 83% (52) of the previously treated patients. Methotrexate administered orally or intramuscularly twice a week maintained the remissions similarly. The median duration of remission for 42 newly treated patients was 10.4 months (orally) versus 8.9 months (intramuscularly), and for 51 previously treated patients it was 5.1 months (orally) and 4.9 months (intramuscularly). The duration of methotrexate-maintained remission was shorter for subsequent remissions especially if a previous remission had been maintained with methotrexate. Possibility of a new type of toxic reaction occurring during methotrexate maintenance is suggested by the high frequency of pneumonitis (38 of 93 children). Other toxic manifestations were controlled by diminished dosages of methotrexate.

Journal

JAMAAmerican Medical Association

Published: Feb 3, 1969

There are no references for this article.